Results 11 to 20 of about 12,502 (244)

Levosimendan: a cardiovascular drug to prevent liver ischemia-reperfusion injury? [PDF]

PLoS ONE, 2013
INTRODUCTION: Temporary occlusion of the hepatoduodenal ligament leads to an ischemic-reperfusion (IR) injury in the liver. Levosimendan is a new positive inotropic drug, which induces preconditioning-like adaptive mechanisms due to opening of ...
Peter Onody, Rita Stangl, Andras Fulop, Oliver Rosero, David Garbaisz, Zsolt Turoczi, Gabor Lotz, Zoltan Rakonczay, Zsolt Balla, Viktor Hegedus, Laszlo Harsanyi, Attila Szijarto   +11 more
doaj   +5 more sources

Levosimendan for sepsis-induced myocardial dysfunction: friend or foe?

Frontiers in Cardiovascular Medicine
Sepsis-induced myocardial dysfunction (SIMD) involves reversible myocardial dysfunction. The use of inotropes can restore adequate cardiac output and tissue perfusion, but conventional inotropes, such as dobutamine and adrenaline, have limited efficacy ...
Xinxin Du, Xinxin Du, Fang Xiong, Yafei Hou, Xiangyou Yu, Pengfei Pan   +5 more
doaj   +2 more sources

Levosimendan in Sepsis [PDF]

New England Journal of Medicine, 2017
Commentum to "Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis"
Putzu A, Belletti A, ZANGRILLO, ALBERTO
openaire   +14 more sources

Early Levosimendan Administration Improved Weaning Success Rate in Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock

Frontiers in Cardiovascular Medicine, 2022
BackgroundVenoarterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used in patients with refractory cardiogenic shock (CS) or out-of-hospital cardiac arrest.
Yu-Wen Chen, Wei-Chieh Lee, Wei-Chieh Lee, Po-Jui Wu, Hsiu-Yu Fang, Yen-Nan Fang, Huang-Chung Chen, Meng-Shen Tong, Pei-Hsun Sung, Chieh-Ho Lee, Wen-Jung Chung   +10 more
doaj   +2 more sources

Levosimendan, a Promising Pharmacotherapy in Cardiogenic Shock: A Comprehensive Review

European Cardiology Review
Cardiogenic shock (CS) is a critical condition with high mortality rate, as the current management of CS presents significant challenges. Exploration of more effective therapies is necessitated.
Hendri Susilo, Fan Maitri Aldian, Citrawati Dyah Kencono Wungu, Mochamad Yusuf Alsagaff, Henry Sutanto, Chaq El Chaq Zamzam Multazam   +5 more
doaj   +2 more sources

Impact of levosimendan on efficacy and renal function in acute heart failure according to renal function: A perspective, multi-center, real-world registry

Frontiers in Cardiovascular Medicine, 2022
ObjectiveAcute heart failure (AHF) is associated with high mortality. Levosimendan, an inodilator, has proved to increase cardiac output and exert renoprotective effect in AHF.
Han Zhang, Li Jiang, Rui Fu, Ping Qin, Xuan Zhang, Tao Tian, Guang-xun Feng, Yan-min Yang   +7 more
doaj   +2 more sources

Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients

ESC Heart Failure, 2022
Aims Routine, intermittent inotropic therapy (IIT) is still applied in advanced heart failure (HF) patients either as a bridge to definitive treatment or as a mean to improve quality of life (QOL), despite limited evidence to support its' use.
Assi Milwidsky, Shir Frydman, Michal Laufer‐Perl, Ben Sadeh, Orly Sapir, Yoav Granot, Aviram Hochstadt, Liuba Korotetski, Liora Ketchker, Yan Topilsky, Shmuel Banai, Ofer Havakuk   +11 more
doaj   +2 more sources

Levosimendan in Cardiac Arrest (LeiCA): Protocol for a Randomized, Double-Blind, Phase II Clinical Trial. [PDF]

Acta Anaesthesiol Scand
ABSTRACT Background Despite developments in advanced life support, outcomes after out‐of‐hospital cardiac arrest (OHCA) remain poor. Levosimendan, a calcium‐sensitizing inodilator commonly used in heart failure, has shown beneficial effects in several experimental models and anecdotal clinical cases of cardiac arrest. The Levosimendan in Cardiac Arrest
Rysz S, Flam B, Hedberg M, Galmén K, Mårtensson J, Djärv T, Jonsson Fagerlund M.   +6 more
europepmc   +2 more sources

Successful Use of Levosimendan in Four Critically Ill Neonates With Pulmonary Hypertension: A Case Series. [PDF]

Pediatr Pulmonol
Pediatric Pulmonology, Volume 60, Issue 12, December 2025.
Kantzavelou A, Chatzigiannis N, Baltogianni M, Atzemoglou N, Giapros V.   +4 more
europepmc   +2 more sources

Potentiating Cerebral Perfusion Normalizes Glymphatic Dynamics in Systemic Inflammation. [PDF]

Adv Sci (Weinh)
LPS‐induced systemic inflammation increases glymphatic influx but delays cervical lymphatic drainage, accompanied by AQP4 depolarization and impaired glymphatic clearance. Enhancing cerebral blood flow via the inotropic agent levosimendan effectively restored AQP4 polarization, improving glymphatic flux and amyloid‐β clearance.
Zhao R, Sun B, Wei P, Sun Y, He Q, Zhang K, Lu J, Zhu S, Yang Y, Guo Z.   +9 more
europepmc   +2 more sources